Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Neuronetics, Inc. (STIM)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.71+19.69%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for STIM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Optimize cost structure with workforce reduction | Cost cuts with a 5% workforce reduction improve efficiency. | Intact | Workforce reduction delayed or expanded beyond 5% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth and execution story, not an established durable compounder, because the business is still loss-making. The long-term thesis is intact, with recent results holding up, but management volatility and limited confidence in the valuation evidence call for caution in how firmly that view is held.
The snapshot describes STIM as cheap versus peers, while also showing a 34% premium versus peers and low model confidence. The expectations gap is strongly negative, suggesting expectations are low, but the evidence does not make the valuation signal clear-cut; the priced-in assessment is marked justified, with no fragility flags.
Near term, execution has been mixed: first-half revenue grew 9%, gross margin reached 51.1%, and operating expenses fell 12%, while 2026 revenue guidance was reaffirmed. A recent earnings event was marked positive, but a prior guidance reduction, a CFO transition, and a history of a deep miss keep execution risk high.
The favorable case depends on guidance improving after its recent reduction and continued delivery on revenue, margins, and cost control. The near-term risk is weaker employment data raising recession concerns, while continued strength from healthcare peers could support the sector backdrop.
Over the next 1 to 3 years, the thesis rests on sustained operating progress and a recovery in guidance, against a high-risk, loss-making base. The evidence is mixed and valuation confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company targets a stable gross margin of 47%-49%. |
| Intact |
| gross margin falls below 47% in FY26 |
Gross margin: 52.17% FY2026-Q3; GAAP. Published target: 47%-49% gross margin. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202652.166246 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Operating expenses between $92.5 million and $95.5 million, compared to prior guidance of $95 million to $100 million.” “On this basis, operating expenses are expected to be $91 million to $96 million, with estimated stock-based compensation of $4 million.” Delivery assessment Nov 4, 2026 |
Achieve $160M-$166M revenue in 2026 | A primary condition in Neuronetics, Inc.'s published investment case. The stated target is >= $160M total revenue. | Intact | annual revenue falls below $147M in FY26 | Revenue: $41.962M FY2026-Q3; GAAP. Published target: >= $160M total revenue. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 202641,962,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.34 → $-0.28 · observed estimates
$0.18B → $0.18B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-07-25 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-07-26 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-07-27 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-07-28 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-07-29 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-07-30 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-07-31 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-01 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-02 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-03 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-04 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-05 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-06 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-08 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-09 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-10 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-12 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-13 | $-0.34 | $177,177,000 | 4 / 4 |
| 2026-08-14 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-15 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-16 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-17 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-18 | $-0.34 | $177,177,075 | 3 / 3 |
| 2026-08-19 | $-0.34 | $177,177,075 | 2 / 2 |
| 2026-08-20 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-21 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-22 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-23 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-24 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-25 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-26 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-27 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-28 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-29 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-30 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-08-31 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-01 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-02 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-03 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-04 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-05 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-06 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-07 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-08 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-09 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-10 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-11 | $-0.29 | $176,933,333 | 1 / 2 |
| 2026-09-12 | $-0.28 | $177,000,000 | 2 / 2 |
| 2026-09-13 | $-0.28 | $177,000,000 | 2 / 2 |
| 2026-09-14 | $-0.28 | $177,000,000 | 2 / 3 |
| 2026-09-15 | $-0.28 | $177,000,000 | 2 / 3 |
| 2026-09-16 | $-0.28 | $177,000,000 | 2 / 3 |
| 2026-09-17 | $-0.28 | $177,000,000 | 2 / 3 |
| 2026-09-18 | $-0.28 | $177,000,000 | 2 / 3 |
| 2026-09-19 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-20 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-21 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-22 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-23 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-24 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-25 | $-0.28 | $177,005,000 | 2 / 3 |
| 2026-09-26 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-09-27 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-09-28 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-09-29 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-09-30 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-01 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-02 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-03 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-04 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-05 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-06 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-07 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-08 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-09 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-10 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-11 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-12 | $-0.28 | $176,955,000 | 2 / 3 |
| 2026-10-13 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-14 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-15 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-16 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-17 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-18 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-19 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-20 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-21 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-22 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-23 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-24 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-25 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-26 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-27 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-28 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-29 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-30 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-10-31 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-11-01 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-11-02 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-11-03 | $-0.28 | $176,950,000 | 2 / 3 |
| 2026-11-04 | $-0.28 | $176,950,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.